Avadel Pharmaceuticals (AVDL) announced that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Most recently, he led Patient Access Partner Operations at Takeda Pharmaceuticals (TAK), where he directed teams in support of Takeda’s USBU Portfolio including Rare Disease Patient Services Programs.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals price target lowered to $14 from $22 at UBS
- UBS cuts Avadel target, says shares ‘significantly cheap’
- Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz
- Oppenheimer cuts Avadel target, would buy on weakness
- Avadel Pharmaceuticals price target lowered to $17 from $23 at Craig-Hallum